|
|
Article: Avastin, Erbitux Pace Up In Colorectal Market Race.(Survey)
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Colorectal cancer - the devilish killer that can show up in the hidden places implied by its name, as well as the appendix and anus - remains the second leading cause of cancer deaths among men and women combined, behind only lung cancer in the U.S.
About 147,000 new cases are expected to be diagnosed this year, and more than 56,000 patients will die from colorectal cancer (CRCA), a sad state of affairs that opens the door wide for Avastin (bevacizumab) and Erbitux (cetuximab). Uptake of both on the market are "tracking ahead of our and [Wall Street's] expectations," according to research by SG Cowen & Co. in New York.
"It's ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cel-Sci Acquisition Inc., of the British Virgin Islands, ...
BIOWORLD Today;
August 23, 1999 ;
700+ words
... ... Corp.'s legal counsel. (See BioWorld Today, Aug. 20, 1999, p. 1 ... Bristol-Myers Squibb Co., of New York, as part of its license and ... 87 million in cash. (See BioWorld Today, Aug. 3, 1999, p. 1 ...
|
|